Login to Your Account



Deals And M&A NEWS
SPECIALTY PHARMA TO DIVERSIFY ITS PRODUCT LINES
Seeking to further diversify its product lines, specialty pharma Amag Pharmaceuticals Inc. will pay $600 million in cash plus $75 million in stock, or approximately 3.2 million newly issued shares, to purchase privately held Lumara Health Inc. (previously K-V Pharmaceutical Co.).
In a deal valued at up to $410 million, Tokyo's Daiichi Sankyo Co. Ltd. offered to buy San Diego-based Ambit Biosciences Inc., along with its pivotal-stage cancer drug quizartinib.
Following an approval in India, a U.S. biosimilars maker has partnered with its investor in China to expand its presence in emerging markets. Livzon Mabpharm Inc. entered a collaboration agreement with Boston-based Epirus Biopharmaceuticals Inc. focused on the development and commercialization of MAbs.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: